# REINVENTING DRUG DISCOVERY

ABOUT

#### For over 30 years, our mission has been to use the power of science to bring new medicines to patients... over and over again.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physicianscientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary *VelociSuite®* technologies, such as *VelocImmune®*, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

Mylan v. Regeneron IPR2021-00881 U.S. Pat. 9,254,338 Exhibit 2246

Every day, we apply technologies and release people with serious disease us.

2020 was a challenging but inspiring year: from creating a new medicine in record time while advancing a diverse pipeline to delivering needed medicines despite pandemic conditions.



DOCKE.

2020 Annual Report

#### Regeneron News: Oct 22nd

Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this

### **Regeneron by the numbers**

30+

years of scientific leadership

9K+

employees worldwide

#### 3rd

consecutive year as one of Fast Company Best Workplaces for Innovators

9

FDA-approved medicines

1.4M+ exomes sequenced to date

OCKF

#1

ranking in Science magazine's global Top Employer survey for six of the past nine years

#### 98%

of our waste diverted from landfill, surpassing our 2025 global responsibility goal

175+ peer-reviewed publications in 2020

#### ~1.1K+

employees with an MD, PhD or PharmD degree

3,000+

volunteers for virtual Day for Doing Good 2020

#### ~100%

of drug candidates invented and developed in-house

30+

product candidates in clinical development across multiple therapeutic areas

#### Honors and awards

Fast Company: Best Workplaces for Innovators, 2021 Great Place To Work: Fortune 100 Best Companies to Work For, 2021 Great Place to Work Ireland: Best Workplaces, 2021 Great Place to Work Ireland: Best Workplaces for Women, 2021 Fast Company: World Changing Ideas (Pandemic Response), 2021 IDEA Pharma: Pharmaceutical Invention Index, 2021 Science: Top Employer, 2020 Fortune: Change the World, 2020 Forbes: JUST Companies, 2020 Dow Jones Sustainability World Index, 2020 Dow Jones Sustainability North American Index, 2020 Newsweek: America's Most Responsible Companies, 2020



### Led by science

We are the only biopharma company founded and led by physician-scientists since the beginning, more than three decades ago. From our first days, science was and remains our central guiding principle. Our leadership includes multiple Nobel Laureates and five members of the National Academy of Sciences, and we are one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

GET TO KNOW THE TEAM

#### **Featured perspectives**

The stories and opinions behind our work.



RAISING THE BAR FOR CORPORATE RESPONSIBILITY IN THE BIOTECH INDUSTRY

By: Hala Mirza Senior Vice President, Corporate Communications and Citizenship

MORE PERSPECTIVES



#### WORKING TOGETHER TO PROVIDE COVID-19 TESTING COMPONENTS

By: Dan Van Plew Executive Vice President and General Manager, Industrial Operations and Product Supply

## A look back

Science isn't easy and new medicines aren't made over night. Decades of investment and perseverance have brought us to where we are today.

VIEW OUR HISTORY





#### **Contact us**

See our U.S. and European locations and contact information.

<u>GET IN TOUCH</u>



REGENERON SCIENCE TO MEDICINE

У in f 🞯

N Terms of Use

Site Map

Social Media Terms of Engagement Privacy Notice Accessibility Statement INVESTORS AND MEDIA

<u>CAREERS</u> >

ireland >

COVID-19 ANTIBODY PROGRAM >

Copyright @ 2021 Regeneron Pharmaceuticals Inc. All rights reserved. All trademarks mentioned are the property of their respective owners.

